ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3
First Claim
1. An antibody or an antigen-binding fragment thereof comprisinglight chain complementarity determining regions (CDR) 1, 2 and 3, wherein light chain CDR 1 is SEQ ID NO:
- 14 or SEQ ID NO;
24, light chain CDR 2 is SEQ ID NO;
15 or SEQ ID NO;
25 and light chain CDR 3 is SEQ ID NO;
16 or 26;
orheavy chain complementarity determining regions (CDR) 1, 2 and 3, wherein heavy chain CDR 1 is SEQ ID NO;
17 or SEQ ID NO;
27, heavy chain CDR 2 is SEQ ID NO;
18 or SEQ ID NO;
28 and heavy chain CDR 3 is SEQ ID NO;
19 or 29.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
-
Citations
27 Claims
-
1. An antibody or an antigen-binding fragment thereof comprising
light chain complementarity determining regions (CDR) 1, 2 and 3, wherein light chain CDR 1 is SEQ ID NO: - 14 or SEQ ID NO;
24, light chain CDR 2 is SEQ ID NO;
15 or SEQ ID NO;
25 and light chain CDR 3 is SEQ ID NO;
16 or 26;
orheavy chain complementarity determining regions (CDR) 1, 2 and 3, wherein heavy chain CDR 1 is SEQ ID NO;
17 or SEQ ID NO;
27, heavy chain CDR 2 is SEQ ID NO;
18 or SEQ ID NO;
28 and heavy chain CDR 3 is SEQ ID NO;
19 or 29. - View Dependent Claims (2, 3, 4, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
- 14 or SEQ ID NO;
-
5. An antibody or an antigen-binding fragment thereof comprising
a light chain variable region amino acid sequence 90% identical to SEQ ID NO: - 12 or SEQ ID NO;
22;
ora heavy chain variable region amino acid sequence 90% identical to SEQ ID NO;
13 or SEQ ID NO;
23. - View Dependent Claims (6, 7, 8)
- 12 or SEQ ID NO;
Specification